Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATGC-110 vs Xeomin for Glabellar Lines
NCT05623410Phase 3Unknown
- Sponsor
- ATGC
- Start
- Oct 2022
- Primary completion
- Feb 2023
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of letibotulinumtoxinA in glabellar frown lines (2 arms), sponsored by ATGC. Primary endpoint: Improvement rate of glabellar lines at maximum frown according to the investigator's on-site evaluation at 4 weeks. Status: unknown.
02
Drugs
letibotulinumtoxinA
03
Conditions
glabellar frown lines
Beyond the preview
Go deeper on NCT05623410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05623410.